Research Article

An Ad Hoc Random Initialization Deep Neural Network Architecture for Discriminating Malignant Breast Cancer Lesions in Mammographic Images

Andrea Duggento,1 Marco Aiello,2 Carlo Cavaliere,2 Giuseppe L. Cascella,3,4 Davide Cascella,5 Giovanni Conte,5 Maria Guerrisi,1 and Nicola Toschi1,6,7

1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
2IRCCS SDN, Naples, Italy
3Idea 75 s.r.l., Bari, Italy
4DEI-Politecnico di Bari, BARI, Italy
5GEM ICT s.r.l., Bari, Italy
6Department of Radiology, “Athinoula A. Martinos” Center for Biomedical Imaging, Boston, MA, USA
7Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Andrea Duggento; duggento@med.uniroma2.it

Received 1 August 2018; Accepted 2 May 2019; Published 22 May 2019

Academic Editor: Alexander R. Haug

Copyright © 2019 Andrea Duggento et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Breast cancer is one of the most common cancers in women, with more than 1,300,000 cases and 450,000 deaths each year worldwide [1]. In the era of precision medicine [2], the identification and stratification of breast lesions in the early stage of cancer development is an essential starting point for increasing the probability of therapeutic success. In this context, early detection of breast lesions through mammography has been seen to be associated with an extremely high probability of cure, with a 97% survival in five years [3]. To date, however, identification of breast cancer lesions is affected by an unsatisfactory rate of false-positive results.

1. Introduction

Breast cancer is one of the most common cancers in women, with more than 1,300,000 cases and 450,000 deaths each year worldwide [1]. In the era of precision medicine [2], the identification and stratification of breast lesions in the early stage of cancer development is an essential starting point for increasing the probability of therapeutic success. In this context, early detection of breast lesions through mammography has been seen to be associated with an extremely high probability of cure, with a 97% survival in five years [3]. To date, however, identification of breast cancer lesions is affected by an unsatisfactory rate of false-positive results.
Currently, X-ray mammography represents the standard breast screening technique. The false-positive and false-negative rates resulting by mammography are relatively high, especially for patients with very dense breasts [4, 5]. The sensitivity of mammography is further influenced by age and ethnicity of patients, personal history, implementation and (especially) expertise, and experience of the radiologist performing the exam. In addition, the mammographic exam does not provide any indication about probable disease evolution and/or outcome (and neither does it provide clues about possibly appropriate therapeutic choices). In this context, it is not surprising that the rate of false-negative or -positive results for mammography described in the literature is extremely variable. While it is evident that possibly high rates of false-negative results are critical, false positives also carry significant consequences. A recent retrospective investigation of registry data concerning 405,191 women aged 40 to 89 years, screened with digital mammography between 2003 and 2011, reported a rate of 12.12% of false-positive results. However, others studies indicate a rate of false positive of up to 20% in specific centers [6]. While a single study computed a very low rate of false-negative results (0.1 to 0.5%) regardless of the patient’s age, several retrospective analyses indicated that mammographic examinations are associated with a high false-negative rate (between 8 and 16%), which is often quoted as an average 15%. These results, apparently controversial, can be explained by the numerous factors that influence the interpretation of mammographic images such as quality of instrumentation, radiologist’s experience, and the availability of a second opinion [7–11]. Also, false-positive mammograms are often associated with increased short-term anxiety but no long-term anxiety and no measurable health utility decrement [11]. In a recent study, a false-positive result increased women’s motivation to undergo future breast cancer screening, whilst it did not increase their self-reported motivation to travel to avoid a false-positive mammogram [12]. Also, in presence of false-positive cases, patients are frequently subjected to repeated invasive (biotic examination) and/or stringent follow-up programs, such as additional mammography exams mammography or equivalent medical procedures which, on top of possibly generating health detriment on their own, also carry significant financial burden. The direct breast-care costs in the year following a false-positive screening mammogram are approximately 5005 higher than in the case of a true-negative result [13].

In view of the above, the introduction of novel artificial intelligence (AI) technologies applied to the diagnosis and possibly prognosis of breast cancer could revolutionize the current status of the management of the breast cancer patient. The support of AI in the diagnostic path of breast cancer patients can potentially both reduce the healthcare costs due to misdiagnosis and promote the achievement of new precision medicine protocols [14]. In this context, the disruptive innovation in computer vision brought about through what is known as deep learning [15–17], and in particular, a class of methods known as deep convolutional neural networks (CNNs) [18] is very quickly making its way into the world of medical imaging. Accordingly, in a preliminary study, Chougrad et al. [13] described a CAD based on deep CNN able to discriminate between malignant and benign breast mass in mammographic images with high accuracy. Likewise, other papers employed massive transfer learning approaches (GoogleNet and AlexNet) [19–21] and compared them to in-house, random initialization models showing that the latter achieves fairly poor performance. Other authors focused on a relatively small dataset and an “in-house” architecture measuring the relationship between network depth and model performance [22]. Still, published results are often hard to validate and replicate also due to the lack of a shared, standard curated dataset of informative mammographic images, and transfer learning approaches may not perform equally well when applied to datasets which are too distant in nature from the application at hand.

The main aim of this study was to design an ad hoc random initialization “in-house” deep neural network architecture to classify/detect breast lesion and explore whether satisfactory performance can be obtained without having to include the inaccurately trained, albeit powerful, public models currently available for transfer learning. Given the strong dependence of CNN performance on the specific task, we aimed to distill what are the key characteristics of a CNN suitable for breast lesion classification. We based our investigation on the recently released Curated Breast Imaging Subset of the Digital Database for Screening Mammography, which is curated by trained radiologists as well as pathologists.

2. Methods

2.1. Dataset. The training and testing of our CNN is done over the Curated Breast Imaging Subset of DDSM Digital Database for Screening Mammography (CBIS-DDSM) [23, 24], which is a collection of mammograms from several sources (Massachusetts General Hospital, Wake Forest University School of Medicine, Sacred Heart Hospital, and Washington University of St. Louis School of Medicine). The database collects both mediolateral oblique (MLO) and craniocaudal (CC) views of each breast. Each breast view is annotated with regions of interest (ROIs) for masses manually drawn (freehand) by expert radiologists and automatically included in a rectangular section of the image. Other annotations include the Breast Imaging Reporting and Data System (BI-RADS) descriptors for mass shape, mass margin, and breast density; overall BI-RADS assessment ranged from 0 to 5; rating of the subtlety of the abnormalities ranged from 1 to 5. Table 1 provides summary of the annotations available for each image.

2.2. Workflow and Architecture Overview. Our model was developed by combining the TensorFlow [25] and Keras [26] libraries; the whole workflow (Figure 1) consists of the following: (i) image preprocessing as described above; (ii) data augmentation; (iii) CNN training; (iv) performance evaluation with respect to a validation set, which allows to compare models trained on the training set; and (v) final
### 2.2.1. Image Preprocessing

Every mass/ROI (Figure 2) is labeled either as "benign" or "malignant" according to pathological findings. As input, we employed all the pre-segmented ROIs containing images of masses, retaining only the "benign"-"malignant" label and hence stripping any other information (Figure 1). Starting from a training set of 1318 images and a test set of 378 images, we created a training set of 1158 images, a validation set of 160 images, and retained the original test set of 378 images.

### 2.2.2. Data Augmentation

It is common practice to synthetically increase the information available to the CNN by applying multiple transformations to the training set [27]. This practice is called "augmentation" and serves the purpose of providing the learning algorithm with as many informative images as possible in order to prevent overfitting (i.e., an excessive specialization of the CNN to the data at hand, which occurs when the training dataset is not sufficiently large to allow for generalization). Accordingly, for each extracted ROI, we perform data augmentation by transforming the training images employing random rotations, rescalings, and shear deformations (it is important to note that since CNNs are not invariant for affine transformations, this process is actually able to inject new training information into the dataset). Figure 3 shows an example of a batch of images resulting from the augmentation process.

### 2.2.3. Training

The process of training consists in tuning the weights of the model (see following paragraphs), to maximize the loss function of the model and hence the accuracy of the automatic classification/diagnosis formulated by the model. Batches of images from the CNN training set are fed into the algorithm, and the weights of the model are updated by the model. Batches of images from the CNN training set are fed into the algorithm, and the weights of the model are updated.

#### (1) Convolutional Layers

Convolutional layers are the first stages of the actual image processing pipeline (Figure 4), and their role is to distill information regarding spatially correlated features of the input image. Convolutional layers function in a way that resembles the physiology of early pathways of the visual cortical areas in humans, where neurons respond to simple tuning—e.g., a neuron might be sensitive to vertical contrasts while another to horizontal contrasts. For example, convolution processes may highlight edges, or smooth the image, or make contrasts in a specific direction more prominent. At each layer, convolved images are subsampled to reduce resolution and passed to the next layer. Each convolutional layer extracts features using as input a linear combination of the outputs of the previous layer. Recursively, more and more (but smaller and smaller) images are produced, each containing information about an intricate combination of features. To the human eye, the images produced after the last layers typically look completely unrelated to the original input. A more technical description of this process can found in [29]. The convolutional part of the CNN is described by the number of convolutional layers, the number of convolutional kernels in each layer and their sizes, the details of the activation functions, and other image processing steps (e.g., how the subsampling is done and whether there is a global-normalization step).

#### (2) Neural Layers

The output of the last convolutional layer is the input to a series of one or few layers of neuronal arrays. A neuronal array is a set of weighted switch-like
discriminators that, much like the firing of a neuron excited by a suprathreshold stimulus, activate when a certain combination of features is active. Again, stacking two or more neuronal layers allows to extract more and more sophisticated combinations of features. Such neural layers are called “fully-connected” because each neuron is linked a priori with any element (a voxel in an image or a neuron) of the previous layer. The weights of those links are tuned during the training process. In our model, the very last layer is composed by a single neuron with a sigmoid activation, i.e., its output is a number between 0 and 1, which describes the algorithm’s educated guess regarding the malignancy of (the mass depicted in) the image (0: completely benign, 1: completely malignant). Varying the threshold on this...
2.2.4. Performance Evaluation during Model Training and Model Selection. At each epoch, we test the diagnostic accuracy of the model on a separate validation set (see above) which, importantly, is not used (i.e., it is completely “unseen”) for training, thus providing an unbiased evaluation tool. For example, a high accuracy on the training set coupled with a low accuracy on the validation set is a good indication of overfitting that has occurred.

It is important to note that, for real-life problems, there is no simple way to choose the best model architecture. Very similar architectures can perform differently, while very different architectures in terms of depth, number of layers, or number of parameters perform could perform almost equally. In this paper, we heuristically explored the space of number of possible architectures and trained them in order to gain insights into what an optimal CNN architecture for classification of breast lesions may be. In particular, we explored (though not exhaustively) the space of the following parameters: number of convolutional layers (2−5), size of the input image (from 78 to 612 pixels, depending on architecture and dimensions of images after the last convolutional layer, which in turn ranged from 1 to 8 pixels), number of convolutional kernels per each layer (from 4 to 64, not necessary identical on every layer), size of the convolutional kernel (from 3 to 11, not necessary identical on every layer), size of pooling (from 2 to 4, depending on the image size and kernel size), method for the last layer vectorization (global mean, global max, or flattening), number of fully connected layers before the last single-neuron layer (from 1 to 3), and numbers of neurons in each fully connected layer (from 200 to 5, typically decreasing with depth of the layer), for a total of 260 tested architectures. Every architecture was evaluated according to its performance on the validation set according to two separate criteria: (a) highest area under the ROC curve (AUC) (“model 1”) and (b) best F2 score amongst all best F2 statistics attained by every single architecture (“model 2”). The F2 score is defined as

\[ F_2 = \frac{5 \times \text{precision} \times \text{recall}}{4 \times \text{precision} + \text{recall}} \]

Within each model, the optimal operating point was chosen according to the F1 score (i.e., maximizing the harmonic average of precision and sensitivity, a commonly adopted criterion which compromises between sensitivity and the ability to discriminate a true positive result) for model 1 and F2 score for model 2.

3. Results

Both “model 1” and “model 2” happened to share the same convolutional architecture: 3 convolutional layers with 64 kernels each; size of kernels in each layer was 7×7, 5×5, and 3×3, respectively; the parameter dropout factor on each convolution was 25%; after rectified linear unit (ReLU) activation, on each layer, a max pooling method with size 4×4, 3×3, and 2×2 (same stride) was employed. “Model 1” and “model 2” differed only in terms of the size of the input images and of the neuronal architecture: “model 1” had an input image of 238×238 pixels and fully connected neuronal layers composed by 50 and 10 neurons each before the last single-neuron layer. “Model 2” had an input image of 286×286 pixels and fully connected neuronal layers composed by 50 and 20 neurons each before the last single-neuron layer. Training the models took approximately 78 hours (4000 training epochs) on a 40-CPU dedicated HP bladesystem. Examples of our result on the validation set as well as final performance of our best models on the test set are shown in Figure 5. Examples of images which are “easy” to classify correctly are shown in Figure 6. Examples of images which are “difficult” to classify correctly are shown in Figure 7.

Our final “model 1” achieved an AUC of 0.785. Detailed performance statistics for this model when selecting an optimal operating point according to the best F1 score method are presented in Table 2. Our final “model 2” achieved an AUC curve of 0.774. Detailed performance statistics for this model when selecting an optimal operating point according to the best F2 score (which is a weighted average between sensitivity—which is emphasized 4-fold—and positive predictive value (PPV)) method are also presented in Table 2.

4. Discussion

While the classical machine learning (ML) paradigm is based on providing a result (i.e., a classification) given a human-defined set of features extracted from input data, CNNs are able to capture intricate relations between image features that are typically invisible to the human eye. Moreover, CNN architectures need not to be problem specific. However, their adaptability with respect to the image classification tasks, and their complete independence from the burden as well as possible bias of human-defined features, comes with the cost of a vast number of parameters which, in turns, require a large amount of training data. Given a certain CNN architecture, if the demand of training data is not met, the performance of the algorithm in terms of classification accuracy might plunge to chance levels. In this pilot study, we have explored the possibility of designing ad hoc CNN architecture with random initialization while studying heuristically which characteristics, out of the multitude of CNN varieties, may be important for breast lesion classification and may warrant further investigation. We employed rigorous validation and test set splits and achieved an area under the ROC curve of 0.78. Additionally, the optimal cutoff point as calculated with an F1 statistics was associated with 62.44% specificity and 84.4% sensitivity. Given the health as well as psychological implications of a false-negative diagnosis in breast cancer (see Introduction), we also strived to select a model which could pose more emphasis on avoided false negatives while still being selected rigorously. We therefore evaluated our model performance at an operating point determined by maximizing the F2 statistic, obtaining a sensitivity of 99.7%. While the specificity of this model may seem low, it is important to note
that, when performing model as well as operating point (i.e., cutoff) selection, it is critical to keep the end-user’s needs and priorities in mind. We therefore put forward that, in a condition like breast cancer where a false negative may have devastating consequences which are overall much more burdensome than those of a false positive, a criterion like the $F_2$ statistic (or similar) may be the instrument of choice.

As noted in the introduction, a few papers based almost exclusively on transfer learning have obtained comparable or higher performance on breast cancer classification as compared to our results. While transfer learning can provide steeper learning rates and asymptotically higher performance when approaching a new classification task and a small training set, it is likely that a

![Figure 5: (a) Receiver operating characteristic (ROC) curves for a subsample of the architectures tested on the validation set (AUCs obtained on the validation set are shown in the legend). (b) ROC curve related to our best performing model (model 1: selected according to AUC on the validation set and model 2: selected according to $F_2$ statistics on the validation set) when evaluated on the test set.](image)

![Figure 6: Example images that are easy to classify: (a) image of a benign lesion that is easily categorized as a benign lesion (score $2.2 \times 10^{-9}$ from model 1 on a scale from 0 to 1); (b) image of a malignant lesion that is easily categorized as a malignant lesion (score 1.0 from model 1 on a scale from 0 to 1).](image)
dedicated learning framework would reach asymptotically higher performance when a large enough training set is made available. Further, one might speculate that the type of background knowledge and the realm of the application are also influential: for a lesion detection problem in mammograms, an architecture well-trained to distinguish (say) cars from the pedestrian might make a worse transfer learning source than, for example, an equally well-trained architecture to distinguish benign from malignant lung nodules.

Of note, the capabilities of a CNN in particular, and of deep learning in general, can, e.g., also be extended to predict molecular alterations (e.g., genetic changes) as long as the training data has been annotated both clinically and genomically in an accurate manner [30]. This could greatly enhance the management of breast cancer patients, in which the choice of therapeutic strategy is currently based on molecular characteristics of breast tumors, which in turn established by histological analysis of biopsies or surgical samples. Specifically, immunohistochemical reactions allow to evaluate the expression of targets for biological (cerB2), anti-hormonal (estrogen receptor), or radiochemical therapies (Ki67) [31–33]. Therefore, one can envisage an algorithm able to predict the molecular features of breast cancer tissues by the analysis of digital mammographic images, which could be conceivably realized by training a CNN jointly with histopathological and molecular data. The introduction of this type of diagnostic approaches has the potential to introduce radical changes in the organization of imaging diagnostic, anatomic pathology, as well as oncology departments. Specifically, the possibility to provide oncologists with possible molecular profiles and/or treatment options at the time of mammography could significantly reduce the need for biopsy investigation, hence optimizing the overall resources available to the healthcare facility. Most importantly, such CAD frameworks could ameliorate the patient’s quality of life by reducing both the number of invasive procedures such as (often repeated) biopsies as well as the average wait before therapy inception. Also, deep learning has the potential to seamlessly integrate data from multimodal imaging of breast cancer, such as mammography and molecular imaging (PET, CT, and MR), with digitalized histological images. The algorithms could be trained to emphasize and highlight morphological signs whose identification is commonly time-consuming to the naked eye but may result in diagnostically actionable items (e.g., microvessel density, neoangiogenesis, lymphovascular invasion, chromatin alteration, or mitotic figures). This type of workflow would not only render pathology and imaging work quick and more accurate but also redefine the role of pathologists to experts able to agglomerate and interpret genetic/molecular, morphological, and imaging information to produce a more integrated and accurate diagnosis [34, 35].

---

**Table 2: Performance statistics for our best performing models as evaluated on the test set.**

| Model 1 (best AUC overall on the validation set, point with best F1 score on the test set) | Accuracy | PPV (precision) | FDR | TPR (recall, sensitivity) | FNR (missrate) | FPR (fall out) | TN (specificity) | F1 score | F2 score | F5 score |
|---|---|---|---|---|---|---|---|---|---|---|
| 71.19% | 59.80% | 40.20% | 84.40% | 15.60% | 37.56% | 62.44% | 70.00% | 77.98% | 63.50% |

| Model 2 (best F2 score overall on the validation set, point with best F2 score on the test set) | Accuracy | PPV (precision) | FDR | TPR (recall, sensitivity) | FNR (missrate) | FPR (fall out) | TN (specificity) | F1 score | F2 score | F5 score |
|---|---|---|---|---|---|---|---|---|---|---|
| 55.93% | 47.40% | 52.60% | 97.16% | 2.84% | 71.36% | 28.64% | 63.72% | 80.30% | 52.81% |

---

**Figure 7:** Example images that are very difficult to classify: (a) image of a benign lesion that is falsely categorized as a malignant lesion (score 0.99992 from model 1 on a scale from 0 to 1); (b) image of a malignant lesion that is falsely categorized as a benign lesion (score .0133 from model 1 on a scale from 0 to 1).
In summary, our pilot study can lay the foundation for the development of new multimodal and multidisciplinary diagnostic tools able to move yet another step towards the goal of realizing a true personalized medicine approach able to take into account the unique peculiarities of every human being.

Data Availability

The images from the Curated Breast Imaging Subset data used for training the algorithms are from previously reported studies and datasets, which have been cited. The processed data are described in (DOI: 10.1038/sdata.2017.177) and currently available at https://wiki.cancerimagingarchive.net/display/Public/CBIS-DDSM.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors wish to acknowledge the Bari ReCaS Data Center (University of Bari “Aldo Moro” and National Institute of Nuclear Physics), coordinated by Prof. G. P. Maggi, for providing access to the high-performance computing resources necessary to conduct this study. The authors also wish to thank Dr. Manuel Scimeca and Dr. Nicoletta Urbano for their expert advice and helpful discussion.

References

[1] D. C. Koboldt, R. S. Fulton, M. D. McLellan et al., “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012.

[2] R. L. N. Godone, G. M. Leitão, N. B. Araújo, C. H. M. Castelletti, J. L. Lima-Filho, and D. B. G. Martins, “Clinical and molecular aspects of breast cancer: targets and therapies,” Biomedicine & Pharmacotherapy, vol. 106, pp. 14–34, 2018.

[3] J. A. Malmgren, J. Parikh, M. K. Atwood, and H. G. Kaplan, “Improved prognosis of women aged 75 and older with mammogram-detected breast cancer,” Radiology, vol. 273, no. 3, pp. 686–694, 2014.

[4] E. D. Pisano, C. Gatsonis, E. Hendrick et al., “Diagnostic performance of digital versus film mammography for breast-cancer screening,” New England Journal of Medicine, vol. 353, no. 17, pp. 1773–1783, 2005.

[5] H. D. Nelson, K. Tyne, A. Naik et al., “Screening for breast cancer: an update for the U.S. Preventive services task force,” Annals of Internal Medicine, vol. 151, no. 10, pp. 727–737, 2009.

[6] S. Hofvind, A. Ponti, J. Patnick et al., “False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of screening programmes,” Journal of Medical Screening, vol. 19, no. 1, pp. 57–66, 2012.

[7] M. G. Wallis, M. T. Walsh, and J. R. Lee, “A review of false negative mammography in a symptomatic population,” Clinical Radiology, vol. 44, no. 1, pp. 13–15, 1991.

[8] E. C. Coveney, J. G. Geraghty, R. O’Laioide, J. B. Hourihane, and N. J. O’Higgins, “Reasons underlying negative mammography in patients with palpable breast cancer,” Clinical Radiology, vol. 49, no. 2, pp. 123–125, 1994.

[9] O. Graf, T. H. Helbich, G. Hopf, C. Graf, and E. A. Sickles, “Probably benign breast masses at US: is follow-up an acceptable alternative to biopsy?”, Radiology, vol. 244, no. 1, pp. 87–93, 2007.

[10] I. G. Murphy, M. F. Dillon, A. O. Doherty et al., “Analysis of patients with false negative mammography and symptomatic breast carcinoma,” Journal of Surgical Oncology, vol. 96, no. 6, pp. 457–463, 2007.

[11] C. H. F. Hill, S. B. Coopey, P. E. Freer, and K. S. Hughes, “False-negative rate of combined mammography and ultrasound for women with palpable breast masses,” Breast Cancer Research and Treatment, vol. 153, no. 3, pp. 699–702, 2015.

[12] A. N. A. Tosteson, D. G. Fryback, C. S. Hammond et al., “Consequences of false-positive screening mammograms,” JAMA Internal Medicine, vol. 174, no. 6, pp. 954–961, 2014.

[13] H. Chougrad, H. Zouaki, and O. Alheyane, “Deep convolutional neural networks for breast cancer screening,” Computer Methods and Programs in Biomedicine, vol. 157, pp. 19–30, 2018.

[14] H. Hampel, N. Toschi, C. Babiloni et al., “Revolution of alzheimer precision neurology. Passageway of systems biology and neurophysiology,” Journal of Alzheimer’s Disease, vol. 64, no. 51, pp. S47–S105, 2018.

[15] Y. Bengio, A. Courville, and P. Vincent, “Representation learning: a review and new perspectives,” IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 35, no. 8, pp. 1798–1828, 2013.

[16] Y. LeCun, Y. Bengio, and G. Hinton, “Deep learning,” Nature, vol. 521, no. 7553, pp. 436–444, 2015.

[17] J. Schmidhuber, “Deep learning in neural networks: an overview,” Neural Networks, vol. 61, pp. 85–117, 2015.

[18] Y. LeCun, K. Kavukcuoglu, and C. Farabet, “Convolutional networks and applications in vision,” in Proceedings of the 2010 IEEE International Symposium on Circuits and Systems, pp. 253–256, Paris, France, May 2010.

[19] L. Shen, “End-to-end Training for Whole Image Breast Cancer Diagnosis using An All Convolutional Design,” 2017, http://arxiv.org/abs/170809427.

[20] D. Lévy and A. Jain, “Breast mass classification from mammograms using deep convolutional neural networks,” 2016, http://arxiv.org/abs/161200542.

[21] W. Hang, Z. Liu, and A. Hannun, GlimpseNet: Attentional Methods for Full-Image Mammogram Diagnosis, Stanford AI Lab Internal Report, Stanford University, Stanford, CA, USA, 2017, http://cs231n.stanford.edu/reports/2017/pdfs/517.pdf.

[22] J. Arevalo, F. A. González, R. Ramos-Pollán, J. L. Oliveira, and M. A. Guevara Lopez, “Representation learning for mammography mass lesion classification with convolutional neural networks,” Computer methods and programs in biomedicine, vol. 127, pp. 248–257, 2016.

[23] M. Heath, K. Bowyer, D. Kopoulos et al., Current Status of the Digital Database for Screening Mammmography, Digital Mammography, pp. 457–460, Springer, Berlin, Germany, 1998.

[24] M. Heath, K. Bowyer, D. Kopoulos, R. Moore, and W. P. Kegelmeyer, “The digital database for screening mammography,” in Proceedings of the 5th International Workshop on Digital Mammography, Medical Physics Publishing, Toronto, Canada, June 2000.

[25] M. Abadi, P. Barham, J. Chen et al., Tensorflow: A System For Large-Scale Machine Learning, OSDI, Savannah, GA, USA, 2016.

[26] F. Chollet, “Keras,” 2015, https://keras.io.
[27] O. Ronneberger, P. Fischer, and T. Brox, "U-net: convolutional networks for biomedical image segmentation," Lecture Notes in Computer Science, vol. 9351, pp. 234–241, 2015.

[28] S. Albelwi and A. Mahmood, “A framework for designing the architectures of deep convolutional neural networks,” Entropy, vol. 19, no. 6, 2017.

[29] M. D. Zeiler and R. Fergus, “Visualizing and understanding convolutional networks,” in Proceedings of the European Conference on Computer Vision—ECCV 2014. D. Fleet, T. Pajdla, B. Schiele, and T. Tuytelaars, Eds., vol. 8689, Lecture Notes in Computer Science, Zurich, Switzerland, September 2014.

[30] M. K. Leung, A. Delong, B. Alipanahi, and B. J. Frey, "Machine learning in genomic medicine: a review of computational problems and data sets," Proceedings of the IEEE, vol. 104, no. 1, pp. 176–197, 2016.

[31] Y. Peng, Y. M. Butt, B. Chen, X. Zhang, and P. Tang, "Update on immunohistochemical analysis in breast lesions," Archives of Pathology & Laboratory Medicine, vol. 141, no. 8, pp. 1033–1051, 2017.

[32] D. Wang, J. Xu, G. Shi, and G. Yin, "Molecular markers’ progress of breast cancer treatment efficacy," Journal of Cancer Research and Therapeutics, vol. 11, no. 1, pp. C11–C15, 2015.

[33] A. C. Wolff, M. E. H. Hammond, D. G. Hicks et al., "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update," Archives of Pathology & Laboratory Medicine, vol. 138, no. 2, pp. 241–256, 2014.

[34] M. Scimeca, N. Urbano, R. Bonfiglio, O. Schillaci, and E. Bonanno, "Management of oncological patients in the digital era: anatomic pathology and nuclear medicine teamwork," Future Oncology, vol. 14, no. 11, pp. 1013–1015, 2018.

[35] O. Schillaci and N. Urbano, "Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 4, pp. 563–566, 2017.